Soy Peptide, Conjugated Linoleic Acid, Overweight or Obese, Body Composition

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-05-14

Study Completion Date

2022-12-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Soybean peptides are a mixture of active peptides obtained from the hydrolysis of soybean protein, which have biological activities such as antioxidant, blood pressure lowering, anti-fatigue and lipid lowering, etc. They can regulate food intake, increase satiety, and reduce fat body ratio by reducing cholesterol and triglyceride content and stimulating CCK secretion.Conjugated linoleic acid (CLA) is a set of linoleic acid with conjugated unsaturated double bond, the location and structure of the isomers have been approved by the ministry of health in China as a new resource food , widely used in areas such as health care products, functional foods and food additives, animal experiments showed that it has reduce tumor, atherosclerosis, obesity risk.Therefore, in this study, the effect of conjugated linoleic acid combined with soybean peptide on overweight and obese people was investigated in a randomized controlled manner.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Black Soy Peptide Supplementation on Blood Pressure

NCT01674491

Hypertension

COMPLETED PHASE3

The Effect of Protein-enriched Diet on Body Composition and Appetite

NCT01634048

Overweight Obese Metabolic Syndrome +1 more

COMPLETED NA

The Effect of Branched-Chain Amino Acid Supplementation and Exercise on Body Composition During Energy Restriction

NCT02630238

Weight Loss Obesity

UNKNOWN NA

The Beneficial Effects of Healthy Snacks on Appetite Control, Satiety, and Reward-driven Eating Behavior in Young People

NCT01781286

Obesity

COMPLETED NA

Protein Supplementation Intervention on Body Weight

NCT06989203

Obesity Weight Loss Protein Supplementation

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Aim 1: To test the effects of combined supplementation of soybean peptide and conjugated linoleic acid on body fat, liver fat and muscle content of overweight and obese people;Aim 2: To test the effects of combined supplementation of soybean peptide and conjugated linoleic acid on blood lipid, blood glucose, fat or inflammatory factors in overweight and obese people; Aim 3: Test the impact of the above interventions on safety indicators (safety indicators: liver and kidney function, self-reported adverse reactions or diseases). Aim 4: To provide scientific basis for the development of functional food for weight loss and muscle gain.The public health significance of this research is that find a new functional food for weight loss and muscle gain.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Overweight or Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental group

2g Soybean peptide, 3g CLA and ng protein.

Group Type EXPERIMENTAL

Experimental group

Intervention Type DIETARY_SUPPLEMENT

Take 1 bag a day with warm boiling water. Intervention: 2g Soybean peptide, 3g CLA and ng protein. They will complete all baseline, 12-weeks, and 24-weeks visits

Control group

2g+N protein and 3g Soybean oil.

Group Type PLACEBO_COMPARATOR

Control group

Intervention Type DIETARY_SUPPLEMENT

Take 1 bag a day with warm boiling water. Intervention: 2g+N protein and 3g Soybean oil. They will complete all baseline, 12-weeks, and 24-weeks visits

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Experimental group

Take 1 bag a day with warm boiling water. Intervention: 2g Soybean peptide, 3g CLA and ng protein. They will complete all baseline, 12-weeks, and 24-weeks visits

Intervention Type DIETARY_SUPPLEMENT

Control group

Take 1 bag a day with warm boiling water. Intervention: 2g+N protein and 3g Soybean oil. They will complete all baseline, 12-weeks, and 24-weeks visits

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Soybean peptide and CLA Protein and Soybean oil

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age - 18-65 years old;
* Gender-not limited;
* BMI-24-35 kg/m2;
* Body fat rate-Male ≥25%, female ≥30% (body fat meter can be used for screening, DXA is used for diagnosis);
* Waist circumference: male \>90cm, Female\>80cm (not required).

Exclusion Criteria

* Suffer from serious diseases such as heart, liver, kidney, brain, hematopoietic, immune, thyroid, malignant tumors;
* Take drugs or supplements that have a known effect on body fat and muscle mass;
* Those whose weight has changed more than 10% in the past 3 months;
* Those who have cognitive or mental disorders and cannot conduct questionnaire surveys;
* People who are physically disabled and cannot walk normally;
* Those whose compliance with the pre-experiment period cannot meet the requirements;
* Fail to sign the informed consent form, or other researchers think it is not suitable for participants

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No